Effect of long-term, low-dose clarithromycin on T helper 2 cytokines, eosinophilic cationic protein and the 'regulated on activation, normal T cell expressed and secreted' chemokine in the nasal secretions of patients with nasal polyposis

Journal of Laryngology and Otology

Volumn 126, Issue 5, 2012, Pages 495-502

  Peric A ^a   Vojvodic D ^a   Matkovic Jozin S ^b  

^a UNIVERSITY OF DEFENCE   (Serbia)

^b Department of Ear   (Norway)

Author keywords

Allergy; Clarithromycin; Cytokines; Eosinophils; Nasal Polyps; Rhinitis

Indexed keywords

CLARITHROMYCIN; EOSINOPHIL CATIONIC PROTEIN; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; RANTES;

ADULT; AGED; ALLERGIC DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EOSINOPHIL; FEMALE; HUMAN; IMMUNOMODULATION; LONG TERM CARE; LOW DRUG DOSE; MALE; NOSE POLYP; NOSE SECRETION; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH2 CELL; TUMOR VOLUME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CHEMOKINE CCL5; CLARITHROMYCIN; CYTOKINES; EOSINOPHIL CATIONIC PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCUS; NASAL MUCOSA; NASAL POLYPS; PROSPECTIVE STUDIES; RHINITIS, ALLERGIC, PERENNIAL; T-LYMPHOCYTES; TH2 CELLS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860827893     PISSN: 00222151     EISSN: 17485460     Source Type: Journal    
DOI: 10.1017/S0022215112000485     Document Type: Article

References (31)

1. Ichimura K, Shimazaki Y, Ishibashi T, Higo R. Effect of new macrolide roxithromycin upon nasal polyps associated with chronic sinusitis. Auris Nasus Larynx 1996;23:48-56 (Pubitemid 26185193)
2. Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol 2000;14:143-8 (Pubitemid 30441214)
3. Cervin A, Wallwork B. Macrolide therapy of chronic rhinosinu-sitis. Rhinology 2007;45:259-67
4. Rhee CS, Majima Y, Arima S, Jung HW, Jinn TH, Min YG et al. Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. Ann Otol Rhinol Laryngol 2000;109:484-7 (Pubitemid 30318261)
5. Nonaka M, Pawankar R, Saji F, Yagi T. Effect of roxithromycin on IL-8 synthesis and proliferation of nasal polyp fibroblasts. Acta Otolaryngol Suppl 1998;539:71-5 (Pubitemid 29111468)
6. Miyanohara T, Ushikai M, Matsune S, Ueno K, Katahira S, Kurono Y. Effects of clarithromycin on cultured human nasal epithelial cells and fibroblasts. Laryngoscope 2000;110:126-31 (Pubitemid 30046658)
7. Pawankar R. Nasal polyposis: an update. Curr Opin Allergy Clin Immunol 2003;3:1-6 (Pubitemid 36159341)
8. Bachert C, Gevaert P, Holtappels G, Van Cauwenberge P. Mediators in nasal polyposis. Curr Allergy Asthma Rep 2002; 2:481-7
9. Nonaka M, Pawankar R, Saji F, Yagi T. Distinct expression of RANTES and GM-CSF by lipopolysaccharide in human nasal fibroblasts but not in other airway fibroblasts. Int Arch Allergy Immunol 1999;119:314-21 (Pubitemid 29401701)
10. Meyer JE, Bartels J, Görögh T, Sticherling M, Rudack C, Ross DA et al. The role of RANTES in nasal polyposis. Am J Rhinol 2005;19:15-20 (Pubitemid 40443999)
11. Saji F, Nonaka M, Pawankar R. Expression of RANTES by IL-1β and TNF-α stimulated nasal polyp fibroblasts. Auris Nasus Larynx 2000;27:247-52 (Pubitemid 30251878)
12. Fokkens W, Lund V, Mullol J, European Position Paper on Rhinosinusitis and Nasal Polyps Group. European position paper on rhinosinusitis and nasal polyps 2007. Rhinology (suppl) 2007;45:1-136
13. Bachert C, Van Kempen M, Van Cauwenberge P. Regulation of proinflammatory cytokines in seasonal allergic rhinitis. Int Arch Allergy Immunol 1999;118:375-9 (Pubitemid 29195578)
14. Perić A, Vojvodić D, Radulović V, Vukomanović-urdević B, Miljanović O. Correlation between cytokine levels in nasal fluid and eosinophil counts in nasal polyp tissue in asthmatic and nonasthmatic patients. Allergol Immunopathol (Madr) 2011;39:133-9
15. Tsicopoulos A, Shimbara A, de Nadai P, Aldewachi O, Lamblin C, Lassalle P et al. Involvement of IL-9 in the bronchial pheno-type of patients with nasal polyposis. J Allergy Clin Immunol 2004;113:462-9 (Pubitemid 38338951)
16. Lildholdt T, Rundcrantz H, Bende M, Larsen K. Glucocorticoid treatment for nasal polyps: the use of topical budesonide powder, intramuscular betamethasone, and surgical treatment. Arch Otolaryngol Head Neck Surg 1997;123:595-600 (Pubitemid 27258448)
17. Pácová H, Kucera T, Astl J, Martínek J. Detection of beta-defensins and NOS in healthy and pathological nasal mucosa. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2004;148:239-40
18. Norlander T, Brönnegård M, Stierna P. The relationship of nasal polyps, infection, and inflammation. Am J Rhinol 1999; 13:349-55
19. Fundová P, Filipovský T, Funda DP, Hovorka O, Holý R, Navara M et al. Expression of IGF-1R and iNOS in nasal polyps; epithelial cell homeostasis and innate immune mechanisms in pathogenesis of nasal polyposis. Folia Microbiol 2008; 53:558-62
20. Lo S, Di Palma S, George E, McCombe AW. Immunolocalisation of heme oxygenase isoforms in human nasal polyps. J Laryngol Otol 2009;123:131-5
21. Bonfils P, Badoual C, Bonfils NA, Gallast D, Malinvaud D. Eosinophil infiltration of nasal polyps in patients with nasal polyposis: role of clinical evaluation after medical and surgical treatment. J Laryngol Otol 2009;123:509-16
22. Cervin A, Kalm O, Sandkull P, Lindberg S. One-year low-dose erythromycin treatment of persistent chronic sinusitis after sinus surgery: clinical outcome and effects on mucoliliary parameters and nasal nitric oxide. Otolaryngol Head Neck Surg 2002; 126:481-9 (Pubitemid 41123534)
23. Haruna S, Shimada C, Ozawa M, Fukami S, Moriyama H. A study of poor responders for long-term, low-dose macrolide administration for chronic rhinosinusitis. Rhinology 2009; 47:66-71
24. Nonaka M, Pawankar R, Tomiyama S, Yagi T. A macrolide antibiotic, roxithromycin, inhibits the growth of nasal polyp fibro-blasts. Am J Rhinol 1999;13:267-72
25. Park HH, Park IH, Cho JS, Lee YM, Lee HM. The effect of macrolides on myofibroblast differentiation and collagen production in nasal polyp-derived fibroblasts. Am J Rhinol Allergy 2010;24:348-53
26. Bartels J, Maune S, Meyer JE, Kulke R, Schlüter C, Röwert J et al. Increased eotaxin-mRNA expression in non-atopic and atopic nasal polyps: comparison to RANTES and MCP-3 expression. Rhinology 1997;35:171-4 (Pubitemid 28109333)
27. Suzaki H, Asano K, Yu M, Hisamitsu T. Influence of roxithro-mycin on inflammatory cytokine production from nasal polyp fibroblasts in vitro. Acta Otolaryngol 2003;123:637-42 (Pubitemid 36831381)
28. Cervin A, Wallwork B, Mackay-Sim A, Coman WB, Greiff L. Effects of long-term clarithromycin treatment on nasal lavage fluid markers of inflammation in chronic rhinosinusitis. Clin Physiol Funct Imaging 2009;29:136-42
29. Bachert C, Wagenmann M, Rudack C, Höpken K, Hillebrandt M, Wang D et al. The role of cytokines in infectious sinusitis and nasal polyposis. Allergy 1998;53:2-13 (Pubitemid 28057357)
30. Fan GK, Wang H, Takenaka H. Eosinophil infiltration and activation in nasal polyposis. Acta Otolaryngol 2007;127:521-6 (Pubitemid 46633786)
31. Liu CM, Hong CY, Shun CT, Hsiao TY, Wang CC, Wang JS et al. Inducible cyclooxygenase and interleukin-6 gene expression in nasal polyp fibroblasts. Arch Otolaryngol Head Neck Surg 2002;128:945-51